Tokyo-based university venture capital firm founded in December 2015 to commercialize academic research and inventions. It invests in seed and early-stage technology startups across healthcare, drug discovery, AI, robotics, space and clean technology, supporting teams from research commercialization through business growth. Initially focused on Keio University spinouts, it broadened its scope to research-based companies beyond Keio in 2020. Its third fund applies impact measurement and management to investments aimed at improving health and well-being alongside financial returns.
Founded
2015
Type
Venture capital
Funds1
KII3, LPS¥20.2B
Third impact venture fund, formally KII Fund No. 3 Impact Investment Limited Partnership, finally closed at ¥20.2 billion on August 13, 2024. It invests in research-based startups across medical and healthcare fields and digital technology, using impact measurement and management to support healthier lives and social outcomes alongside venture returns. Its operating period begins October 11, 2023 and runs for ten years, with a possible two-year extension. The ¥35 billion figure reported at this close is combined firm fund assets, not the size of Fund III.
Fast Track Initiative
Neusignal Therapeutics$— · 2026-06-30
DCI Partners
K Pharma¥1.55B · 2022-05-24
Angel Bridge
Beyond Next Ventures
LIFESCAPES¥720M · 2022-06-20
ITOCHU Technology Ventures, Inc.